Disparities exist in survival among younger patients with acute leukemia
the ONA take:
Disparities in treatment outcomes for younger patients with acute promyelocytic leukemia (APL) exist among uninsured patients and those of Hispanic and black race/ethnicity, according to a new study published online ahead of print in the journal Cancer.
For the study, researchers sought to evaluate disparities in early death and survival in children, adolescents, and young adults with APL in California in the era of all-trans-retinoic acid (ATRA) treatment.
Researchers analyzed data from the California Cancer Registry to assess the 7-day and 30-day mortality and survival in 772 patients younger than 39 years of age with APL who were diagnosed between 1988 and 2011.
Results showed that the overall 30-day mortality decreased from 26% between 1988 and 1995 to 14% between 2004 and 2011, suggesting that the odds of death in the 30 days after diagnosis were 3 times higher during the first time period than the second time period.
Researchers found that lack of insurance and Hispanic and black race/ethnicity were associated with higher early death and reduced survival, suggesting that efforts should be made to improve access to effective treatment among those patients.
Disparities in treatment outcomes for younger patients with acute promyelocytic leukemia (APL) exist.
- Sexual Dysfunction in Women With Cancer: A Review of Available Interventions
- Osteoporosis Medication Improves Bone Health in ADT-Treated Prostate Cancer
- Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia
- Cabazitaxel in Prostate Cancer: Reduced Dose Noninferior to Standard Dose
- Risk of Some Cancers Higher in Women With a History of Periodontal Disease
- To Better Serve Patients With Cancer, Navigators Need Better Systems
- Physical Activity Improves Cognitive Function for Breast Cancer Survivors
- Risk of Lung Cancer Increases With Diets Higher in Saturated Fats
- Mechanisms Identified for Curcumin Resensitization of Cancer Cells
- Value of Type and Crossmatch Prior to Daratumumab Administration
- Affect of Daratumumab on Laboratory Blood Test Results
- Geriatric Consults Rare in Kidney Cancer Care
- Worse Survival Seen for Alternative Versus Usual Cancer Therapy
- Anorexia-Cachexia in Non-Small Cell Lung Cancer Improved With Anamorelin
- Early Recognition of Checkpoint Inhibitor-Related Pneumonitis Improves Outcomes
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|